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Background: Despite intense research, the causes of various neurological diseases remain enigmatic to date. A role
for viral or bacterial infection and associated molecular mimicry has frequently been suggested in the etiology of
neurological diseases, including demyelinating autoimmune disorders, such as multiple sclerosis. Pathogen mimics
of myelin-derived autoimmune peptides have been described in the literature and shown to induce myelin
autoimmune responses in animal models.
Methods: We carried out a structural study on myelin-derived peptides, and mimics thereof from various
pathogens, in aqueous and membrane-like environments, using conventional and synchrotron radiation circular
dichroism spectroscopy. A total of 13 peptides from the literature were studied, and 290 circular dichroism spectra
were analysed. In addition, peptide structure predictions and vesicle aggregation assays were performed.
Results: The results indicate a high level of similarity in the biophysical and folding properties of the peptides from
either myelin proteins or proteins from pathogenic viruses or bacteria; essentially all of the studied peptides folded
in the presence of lipid vesicles or under other membrane-mimicking conditions, which is a sign of membrane
interaction. Many of the peptides presented remarkable similarities in their conformation in different environments.
Conclusions: As most of the studied epitope segments in myelin proteins are associated with membrane-binding
sites, our results support a view of molecular mimicry, involving lipid membrane interaction propensity and similar
conformational properties, possibly playing a role in demyelinating disease. The results suggest mechanisms related
to protein amphiphilicity and order-disorder transitions in the recognition of peptide epitopes in autoimmune
demyelination.
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Myelin is a multilayered, tightly packed proteolipid
membrane structure crucial for the rapid saltatory con-
duction of nerve impulses in vertebrates. It is formed
when the plasma membrane of a myelinating glial cell
wraps around an axon, with eventual compaction driving
out excess cytoplasm and extracellular fluid. Demyelinat-
ing diseases are neurological conditions related to the* Correspondence: petri.kursula@uib.no
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can be caused by inherited mutations, often concerning
myelin-specific proteins, or autoimmune reactions
against myelin components. For most demyelinating dis-
eases, the corresponding molecular mechanisms remain
unknown, directly impairing our understanding of these
disorders and their potential treatment.
Multiple sclerosis (MS) is a central nervous system
(CNS) demyelinating autoimmune disease with a com-
plex, incompletely known etiology. The current under-
standing of the pathogenesis and immunological models
of MS has been reviewed [1, 2]. MS is an autoimmunele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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mechanism, while B cell-expressed autoantibodies likely
play a role in disease progression. Several peptide epi-
topes from myelin proteins, including myelin basic pro-
tein (MBP) [3], proteolipid protein (PLP) [4, 5], myelin-
oligodendrocyte glycoprotein (MOG) [6], and myelin-
associated oligodendrocytic basic protein (MOBP) [7, 8]
have been implicated as T cell epitopes in MS, and many
such peptides have been used to induce experimental
autoimmune encephalomyelitis (EAE), the most widely
used animal model of MS [9]. In addition, the myelin
proteins P0, P2, and PMP22 have similarly been impli-
cated in the peripheral nervous system (PNS) auto-
immune disease Guillain-Barré syndrome (GBS) and its
corresponding animal model, experimental autoimmune
neuritis (EAN) [10–12]. In GBS, a common disease-
preceding infection is by Campylobacter jejuni [13, 14].
It is unclear, how autoreactive T cells are triggered, but
environmental factors play a significant role in MS. Es-
pecially inflammations caused by viral or microbial in-
fections have been implicated. For example, Epstein-Barr
virus infection seems to correlate with MS morbidity [2].
A number of other viral pathogens have also been
implicated in MS etiology [15–18]. The proposed
immunological mechanisms behind infection-induced
autoimmunity include molecular mimicry, bystander ac-
tivation, and dual-specificity T cell receptor (TCR) ex-
pression. While in the latter two mechanisms, the
response towards the infective agent either indirectly or
co-operatively induces autoreactive T cell function, mo-
lecular mimicry predicts immunological identity or close
similarity between the sequences and/or structures of
self-epitopes and viral/bacterial proteins at the molecular
level.
Several viral and bacterial peptides harbour structural
epitopes that mimic the well-characterized immunodo-
minant MBP85-99 peptide, albeit they share very limited
sequence similarity, with only a few conserved amino
acids required for major histocompatibility complex
(MHC) or TCR binding [19]. However, it is not known
whether the self-epitopes are present in the native
physiological state, or whether they form after conform-
ational changes or denaturation caused by insults against
myelinating glial cells and subsequent antigen presenta-
tion. MBP isolated from nerve tissue has been for long
known for its intrinsically disordered structure and con-
formational changes induced by lipids [20–27]; much of
this work stems from isolation of native protein from
tissue, which will inevitably produce heterogeneous sam-
ples. Full-length 18.5-kDa murine MBP and the MBP72-
107 peptide underwent a disordered-to-ordered transi-
tion, when transferred from an aqueous to a membrane-
like environment in a trifluoroethanol (TFE) titration ex-
periment [28, 29]. We observed folding of recombinant18.5-kDa MBP in various membrane-mimetic condi-
tions, as well as in the presence of lipid vesicles [30].
Similarly, the MBP85-99 peptide acquired helical con-
formation in the presence of detergent micelles and lipid
vesicles [31]. The main immunogenic epitope of MBP,
represented by the MBP85-99 peptide, corresponds to
the central membrane attachment site, and correlations
between the strength of the membrane interaction and
MS etiology have been suggested [32]. Taken into ac-
count recent theories on the formation of a protein
phase consisting of MBP upon myelin membrane matur-
ation [33], it is clear that membrane binding and related
conformational changes in MBP are crucial for normal
myelin formation and maintenance.
The above findings raise questions on whether mo-
lecular mimicry in the context of MS may focus on
structural epitopes, which change during water-lipid en-
vironmental transitions. Importantly, conformation-
specific anti-MOG antibodies are required for MS-type
pathological changes in EAE [34]. Therefore, there exists
significant interest to find out, whether the autoimmu-
nogenic epitopes in myelin proteins undergo conform-
ational changes, when shifted between aqueous and
hydrophobic, membrane-like environments, and whether
the pathogen epitopes, which share similar T cell recog-
nition, behave similarly. Could similar behaviour of pep-
tide epitopes from myelin proteins and putative
pathogenic mimics in membrane-mimicking conditions
be correlated to autoimmunogenic properties in the spe-
cific case of demyelinating autoimmune diseases?
Here, circular dichroism (CD) spectroscopy was used
to follow conformational changes in several myelin self-
epitope peptides from PLP, MOBP, MOG, and P2 and in
four MBP85-99-mimicking viral/bacterial peptides in
aqueous and membrane-like environments. All peptides
were picked from relevant literature. We observed that
the autoimmunogenic candidate peptides underwent
folding, when shifted from an aqueous to a hydrophobic
environment. The same change was evident for the
MBP-mimicking peptides. All the results point towards




Synthetic peptides were from GenScript, Piscataway, NJ,
USA. Details of the peptides are given in Table 1. Pep-
tides were dissolved in sterile water to get 10 mg/ml
stock solutions. All peptides were acetylated at the N
terminus and amidated at the C terminus.
Detergents and lipids
n-Dodecyl phosphocholine (DPC) was from Anatrace and
sodium dodecyl sulfate (SDS) from Sigma. Dimyristoyl
Table 1 The peptides selected for the current study
Peptide Sequence Predicted structure References
MOBP15-36 QKFSEHFSIHCCPPFTFLNSKR beta/disordered [7]
MOBP37-60 EIVDRKYSICKSGCFYQKKEEDWI alpha/disordered [8]
hMOG35-55 MEVGWYRPPFSRVVHLYRNGK beta/disordered [6]
mMOG35-55 MEVGWYRSPFSRVVHLYRNGK beta/disordered [6]
HSV-mimic FRQLVHFVRDFAQLL alpha [19]
EB-mimic TGGVYHFVKKHVHES alpha [19]
IA-mimic YRNLVWFIKKNTRYP beta/disordered [19]
PA-mimic DRLLMLFAKDVVSRN alpha [19]
P2gbs ENFDDYMKALGV alpha/disordered [78]
PLP139-151 VSLGKWLGHPDKF alpha/disordered [4]
PLPextra2 FNTWTTCQSIAFPSKTSASIGSLCADARMYG alpha/disordered [5, 60]
PLPintra1 AEGFYTTGAVEQIFGDYKTTICGKGLSATVTGGQKGRG mixed [60, 100]
PLPintra2 SRGQHQAHSLERVCHCLGKWLGHPDKFVGI alpha/disordered [4, 60]
The predicted structure corresponds to that obtained from PEP-FOLD. References for the possible disease linkage of each peptide are also given
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dylglycerol (DMPG) were from Affymetrix. To prepare
lipid vesicles, the lipids were dissolved in 1:1 methanol:-
chloroform. The lipid solutions were then mixed in a 1:1
molar ratio, and solvent was evaporated under a gentle air
stream. The dried lipid mixtures were suspended to 10 or
20 mg/ml in water or 10 mM HEPES (pH 7.5). Hydration
was completed and unilamellar vesicles prepared by se-
quential sonication (30 min Branson 3510 bath sonicator,
followed by 60 s Branson 450 ultrasonifier with 10%
power and a 1 s pulse–1 s chase protocol).
Circular dichroism spectroscopy
Environment-induced folding of peptides was analyzed by
CD spectroscopy, using a Chirascan Plus spectropolarime-
ter (Applied Photophysics). Quartz cuvettes with a 1-mm
light path were used to measure CD spectra from 260 to
190 nm. The samples were water-dissolved peptide sam-
ples of nominal concentrations of 50 to 100 μg/ml, with
or without TFE, detergents, or lipids (added immediately
before the measurement). A peptide form the Plasmodium
falciparum formin was used as a negative control. Syn-
chrotron radiation CD (SRCD) spectra were recorded at
+30 °C on the DISCO beamline at the SOLEIL synchro-
tron (Paris, France) and on the AU-CD beamline at the
ASTRID2 storage ring (ISA, Aarhus, Denmark), using 0.2-
and 0.5-mm quartz cuvettes and 0.25 mg/ml peptide.
In the oriented CD (OCD) experiment, 200 μl of a
peptide-lipid (1:30 molar ratio) mixture, containing
10 μg of peptide, or 200 μl of a DMPC:DMPG (1:1) lipid
blank alone, were pipetted onto a quartz disk. The gen-
eration of multilamellar planar lipid bilayers was con-
ducted by air-drying, followed by 10 h of re-hydration in
a saturated K2SO4 atmosphere at +30 °C (relativehumidity 97%) [31]. OCD spectra were recorded with
45° rotation steps on the DISCO beamline at the
SOLEIL synchrotron (Paris, France), and the resulting
eight spectra, covering 360° of total rotation, were aver-
aged. Due to the rather harsh sample preparation pro-
cedure and the tendency of the peptides to aggregate
membranes, only the EB-mimic peptide gave a high
enough signal for further analysis.
SRCD and OCD spectra were averaged and back-
grounds subtracted with CDtool [35]. A total of 290 CD
spectra were measured and analysed.
Structure prediction and CD deconvolution
De novo structure prediction of the peptides was done in
silico using the PEP-FOLD server [36, 37]. Membrane
association modes of protein and peptide models where
predicted using PPM [38]. Secondary structure contents
were inferred by deconvoluting the CD spectra with the
DICHROWEB server using the CONTINLL algorithm
with DICHROWEB reference databases 6 and 7 for
SRCD and regular CD, respectively [39]. The Bestsel ser-
ver [40] was also used. It should be noted that in the
case of short peptides, deconvolution algorithms opti-
mized for full proteins give semi-quantitative or qualita-
tive results, and we think more information is available
by simply observing and comparing the full spectra, in-
stead of relying on numbers from deconvolution. Spectra
of short peptides are strongly affected by amino acid
composition, for example.
Turbidimetry
Peptide-induced vesicle agglutination was studied in
0.5 mM DMPC:DMPG lipid in water. Peptides or pro-
teins were added at the start of the experiment, and the
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fore [41]. The full-length human P2 protein was used as
a positive control [41]. Another possible positive control
could have been full-length MBP [42].
Turbidity changes as a function of peptide concentra-
tion were followed by absorbance measurement at
450 nm in 96-well format using a Tecan Infinite M1000
Pro plate reader (Tecan, Salzburg, Austria). The total
volume was 150 μl, and 2 s orbital shaking with 1 mm
amplitude and 150 ms settling time were used.Results
Demyelinating autoimmune diseases, such as MS or
GBS, are thought to present a molecular mimicry com-
ponent related to relatively common viral or bacterial
pathogens, many of which involve the nervous system in
their infection. This research was sparked by our interest
in studying putative common biophysical properties be-
tween myelin-derived autoimmune peptides and pep-
tides from pathogens described in the literature and
proposed to cause molecular mimicry in e.g. multiple
sclerosis. Our hypothesis was that such peptides might
share similar properties with respect to structure, con-
formational changes, and lipid membrane binding, and
furthermore, that peptides affecting the CNS and PNS
might have similar properties.Myelin-derived or myelin-mimicking peptides of potential
relevance to demyelinating disease
Nine peptides from four human or mouse compact mye-
lin proteins with a putative autoimmunogenic character
and four viral/bacterial peptides suggested [19] to mimic
the well-known MS-associated MBP sequence (amino
acids 85–99) were chosen for structural analysis; all pep-
tides have been described in the literature earlier (see
Table 1 and references therein). The corresponding
MBP85-99 peptide was a subject of our earlier study
[31]. An additional common denominator of the myelin
protein peptides was known or suggested membrane
contact. The N terminus of MOBP is predicted to have a
membrane-associated FYVE domain [43]. The peripheral
myelin protein P2 acts in the formation of myelin
membrane stacks, with the two α helices involved in
membrane contacts [41, 44]. MOG and PLP are trans-
membrane proteins, in which both the extracellular and
cytoplasmic domains may interact with the next appos-
ing lipid bilayer. In PLP, the autoimmunogenic peptides
are in the close vicinity of the transmembrane domains,
forming loops between them. Finally, pathogen-derived
peptides were predicted to mimic the autoimmunogenic
central membrane-anchoring segment of MBP, which
has been shown to become embedded into the lipid bi-
layer [19, 31, 45–49].Based on amino acid sequences, the peptides do not
exclusively share obvious biophysical characteristics.
However, most of the peptides are positively charged at
neutral pH and contain hydrophobic amino acids, which
may be important for membrane attachment (Additional
file 1: Table S1). The charge distributions are evenly
scattered along the sequence. However, most peptides
showed amphipathic distribution of positively charged
and hydrophobic residues on helical wheel models
(Fig. 6b, Additional file 2: Figure S1), possibly reflecting
propensity for interactions with phospholipid membrane
surfaces. A predicted property for most, but not all, of
the studied peptides is the presence of a membrane-
induced amphipathic helix.
The peptide de novo structure was predicted in silico
using the PEP-FOLD algorithm [36] (Additional file 3:
Figure S2). The MOG-derived peptides, as well as the
Influenza hemagglutinin peptide (IA mimic), were pre-
dicted to harbor β strands, whereas other MBP-
mimicking peptides (HSV mimic, EB mimic, and PA
mimic) as well as the P2-derived peptide P2gbs, con-
tained an α helix as the dominant predicted secondary
structure. The latter corresponds to α helix 1 in the
crystal structure of human P2 [41, 44]. Peptides from
PLP were predicted to consist of α-helical parts with a β
strand (PLPintra1) or disordered sequences (Table 1),
while MOBP15-36 and MOBP37-60 were predicted to
have β strand and α helix, respectively, in addition to
disordered regions (Table 1). While all peptides were ex-
perimentally observed to maintain an unfolded structure
in aqueous solution, these predicted propensities of
folding were, in fact, rather consistent with CD spectro-
scopic experiments under membrane-mimicking condi-
tions (see results below).
During the formation of compact myelin, the periph-
eral membrane proteins of myelin, as well as the extra-
and intracellular domains of integral myelin membrane
proteins, experience change from an aqueous/single
membrane physical environment to a dehydrated mem-
brane multilayer. After mechanical damage, or an
inflammation/infection-induced insult to myelin, an
opposite environmental change is possible, whereby
membrane-embedded epitopes may be exposed to aque-
ous conditions. CD spectroscopy is a powerful method
to probe solvent effects on peptide structure. Previously,
it has been shown that many myelin protein-derived
peptides, indeed, undergo folding, when shifted from
aqueous buffer into a more hydrophobic environment
[31, 50]. We monitored the CD spectra of the 13 se-
lected peptides (Table 1) by conventional and SRCD in
the presence of different concentrations of TFE, DPC,
and SDS, as well as with DMPC:DMPG (1:1) vesicles.
In general, all studied peptides were disordered in
water and showed TFE-, SDS- (a negatively charged
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~0.24%), and lipid vesicle-induced folding at variable
levels, while DPC (a zwitterionic detergent, CMC =
1.1. mM; ~0.04%) did not induce folding of MOBP pep-
tides (see below for details). Of note, a peptide from the
formin of the malaria parasite did not fold upon
membrane-mimicking conditions and was considered a
negative control (Additional file 4: Figure S3). Consist-
ently, CONTINLL predicted higher degrees of folding
and higher α/β ratios than the Bestsel algorithm. How-
ever, these differences were minor in terms of quantity.
Finally, as expected, the diagnostic value of the wave-
length region 180–190 nm, which can be reliably mea-
sured only with SRCD, was significant. This could be
observed by comparing the secondary structure content
deconvolutions between conventional CD (190–260 nm)
and SRCD (180–270 nm), as the programs inferred
conventional CD spectra in favour of β strand content,
which likely arose from random coil structure, as indi-
cated by SRCD data. The results from secondaryFig. 1 Pathogen peptides mimicking MBP85-99 in membrane-like conditio
structure of the MBP72-107 peptide in micelles [46]. c Crystal structure of t
titration of the EB mimic peptide. e Membrane-like conditions induced by
contains the relative signal at 195 nmstructure deconvolution of all 290 CD spectra with both
of the algorithms are given in Additional file 5: Table S2.
MBP85-99-mimicking peptides demonstrate a major
disorder-to-helix transition induced by TFE, micelles, and
lipid vesicles
The four MBP85-99-mimicking peptides (Fig. 1a), ‘HSV-
mimic’ from tripartite terminase subunit 3 (UL15) of
Human herpes simplex virus 1, ‘EB-mimic’ from Epstein-
Barr virus DNA polymerase catalytic subunit (BALF5),
‘IA-mimic’ from Influenza A virus hemagglutinin, and
‘PA-mimic’ from Pseudomonas aeruginosa phosphoman-
nomutase (algC), were selected based on earlier litera-
ture on their properties related to molecular mimicry in
autoimmune response [19]. Structural information for the
corresponding segment in MBP is available (Fig. 1b, c),
and while it is helical when bound to membranes [31, 47],
its conformation is extended when bound to MHC [51].
The residues most conserved between MBP and the
mimic peptides lie slightly embedded in the membrane inns. a Sequence alignment of MBP and the mimicking peptides. b NMR
he MBP epitope bound to MHC [51]. d TFE (left) and DPC (right)
TFE (left), DPC (middle), and SDS (right) for all four peptides. The y axis
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MHC complex; these are the positions that MHC presents
to the T cell. Mutation of these positions in the MBP85-99
epitope lead to altered immunological response [52, 53].
In CD experiments, the mimic peptides were mainly
disordered in water and acquired folded structure after
moving into membrane-like environments (Fig. 1d, e
and Additional file 5: Table S2). This behavior is highly
similar to that of the MBP85-99 peptide [31]. From the
SRCD spectra of peptide-lipid vesicle mixtures (Fig. 2),
CONTINLL and Bestsel, respectively, calculated α-
helical contents of 91 and 79% for EB-mimic, 57 and
58% for HSV-mimic, 63 and 62% for IA-mimic, and 43
and 38% for PA-mimic. Interestingly, while the predicted
structure de novo (Table 1) was helical for EB-mimic,
HSV-mimic, and PA-mimic, IA-mimic was predicted to
have a β strand, which is also present for this segment in
the hemagglutinin protein [54]. Similarly to MOG35-55
(see below), the IA-mimic peptide thus shows, at least as
an isolated peptide, that it has a propensity for helical
conformation under membrane-like conditions. Such
common properties may explain the encephalitogenic
properties of many myelin- and pathogen-derived pep-
tides, despite the context of the corresponding sequence
in the full protein.
The EB-mimic peptide membrane orientation is similar to
MBP85-99
Previously, we [31] have shown by OCD that MBP85-99
is partially embedded into a lipid membrane leaflet in a
tilted orientation. We repeated the experiment here for
the EB mimic peptide, which had the highest helical
content when mixed with vesicles (see above). Briefly,
10 μg of peptide was mixed with DMPC:DMPG (1:1)
vesicles with a 1:30 P/L ratio, and OCD was measured
from planar multilayered membranes. The 208-nmFig. 2 MBP-mimicking peptides in lipidic environment. The top panel show
bottom panel conventional CD spectra at two different P/L ratios. a HSV-mminimum, typical for α-helical conformation, which was
observed in isotropic solution CD spectra, was missing
in OCD (Fig. 3), indicating either a conformational
change or assembly of the peptide in a tilted orientation
in the oriented membrane layers. This observation
supports the hypothesis that the MBP85-99 self-epitope
and the mimic peptides share similar conformational
epitopes.
The MOG35-55 epitope has a propensity to adopt helical
conformation
The MOG35-55 epitope (Fig. 4a) is a widely recognized
inducer of encephalitogenic reactions, and it is routinely
used to induce mouse EAE models [55, 56]. The
mMOG35-55 epitope is highly immunogenic and in-
duces EAE, while the corresponding peptide from human
MOG is less active in causing EAE [57]. This is surpris-
ing, since only one residue distinguishes mMOG35-55
and hMOG35-55 from each other.
Both human and mouse MOG35-55 were largely dis-
ordered in water and acquired α-helical character in
hydrophobic environments (Fig. 4). While these peptides
differ only by a single amino acid (Pro/Ser42), the α/β
ratio was in general higher for hMOG35-55 in
membrane-mimicking conditions (Fig. 4, Additional
file 5: Table S2). The SRCD spectra of the two peptides
with lipid vesicles also suggest more β structure content
for mMOG35-55 (Fig. 4b). In the crystal structure, the
peptide sequence covers two β strands and a connecting
loop [58] (Fig. 4a), which was also predicted for these pep-
tides de novo in aqueous environment (Table 1). However,
based on our results, this autoimmunogenic region in
MOG has an intrinsic propensity to adopt α-helical con-
formation in the context of a peptide interacting with
membranes. Subtle differences in folding between the
mMOG35-55 and hMOG35-55 epitopes may be relevants SRCD spectra in water and with lipid vesicles (dashed line), and the
imic. b EB-mimic. c IA-mimic. d PA-mimic
Fig. 3 Orientation of the EB-mimic peptide on a membrane. The figure shows comparison of isotropic and oriented SRCD spectra. The loss of the
peak at 208 nm in OCD is a sign of tilting of the peptide with respect to the membrane surface plane
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mMOG35-55 peptide have also been linked to altered im-
mune responses in mouse models [59]. Whether the rec-
ognition of the Pro/Ser residue itself or the variant-
favored conformation determines the strength of autoim-
munogenicity remains to be studied.Fig. 4 The MOG35-55 peptides. a Location of the segment 35–55 in the M
glycosylation site Asn31 [101] and the Ser42 residue (at the hairpin of the M
produces a less encephalitogenic response [57]. b SRCD spectra of the hum
presence of lipid vesicles. Similar results were also obtained in conventiona
and mouse (right) peptides. d DPC titration. e SDS titration. Note the differMOBP peptides fold into different structures in
membranes
The N terminus of MOBP, shared by all known MOBP
isoforms, is predicted to fold into a FYVE-like mem-
brane interaction domain [43] (Fig. 5a, b). The epitope
peptide segments correspond to areas predicted toOG Ig domain crystal structure [58]. Shown (as sticks) are also the
OG35-55 epitope), which when mutated to Pro, as in human MOG,
an (top) and mouse (bottom) MOG35-55 peptides in the absence and
l CD at P/L ratios of 1:30 and 1:100. c TFE titration of the human (left)
ent behaviour of both peptides below and above the CMC
Fig. 5 Peptide epitopes from MOBP. a Predicted structure of the FYVE-like domain at the N terminus of MOBP. The regions corresponding to the
peptides studied here are coloured, and potential metal ion-coordinating residues (Cys/His) are shown as sticks. b Predicted interaction [38] of the
model with a membrane surface. c TFE titration of MOBP15-36 (left) and MOBP37-60 (right). d DPC titration. e SDS titration. Note the different
behaviour below and above the CMC. f SRCD spectra in the absence and presence of DMPC/DMPG vesicles. The MOBP37-60 peptide has
pronounced beta content, while MOBP15-36 is more helical
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no high-resolution structural or functional studies with
purified MOBP protein have been carried out. The de
novo prediction suggested some β and α structures for
the MOBP15-36 and 37–60 peptides, respectively, with
disordered regions (Table 1), but in contrast to the
MBP-mimicking and MOG35-55 peptides, models pre-
dicted by PEP-FOLD were not always consistent.
Both MOBP peptides (15–36, 37–60) showed
hydrophobicity-induced folding (Fig. 5b–f ). DPC induced
some secondary structure formation at high concentra-
tions (Fig. 5d), while both peptides behaved differently in
SDS. Below the CMC of SDS, the CD spectra arereminiscent of β aggregates, while above the CMC, mi-
celles of SDS induce significant helical components
(Fig. 5e). The SRCD spectra of lipid vesicle-induced fold-
ing suggested a β sheet structure for MOBP37-60, while
MOBP15-36 contains more helical structure (Fig. 5f).
While these results differ somewhat from the other pep-
tides in this study, which form α-helical structures under
most conditions, they are logical and fit to the predicted
FYVE domain structure of MOBP [43].
PLP-derived peptides fold in hydrophobic environments
The peptides from PLP were based on earlier studies on
EAE models, and included both extra- and intracellular
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related to demyelination in EAE [60, 61]. In the overlap-
ping peptides PLP139-151 and PLPintra2, a region with
strong propensity to fold into an amphipathic helix can
be detected (Fig. 6b, c). Remarkably, all the PLP peptides
also exhibited folding in membranous environments, al-
though they are expected to represent loops between the
transmembrane helices in the PLP protein (Fig. 6d, e).
The result strongly suggests that these loops are able to
interact directly with lipid membrane surfaces. In the
case of compact myelin, this could lead to a single mol-
ecule of PLP acting as glue between three successive
membrane layers. Interestingly, a C-terminal peptideFig. 6 PLP-derived peptides. a Schematic structure of PLP. The peptide col
shown by red sequence. Potential palmitoylation sites are also indicated. b
PLP139-151) peptide. c Predicted membrane association of the C-terminal ha
of PLP peptides in membrane-mimicking conditions. From left to right: typica
relative signals at 195 nm in the presence of TFE, DPC, and SDS for all peptide
PLPintra2, PLP139-151, PLPextra2) at different P/L ratios in the presence of DMfrom PLP was also recently shown to fold upon mem-
brane interaction, and the folding was affected by pep-
tide concentration, the helices refolding into β sheet
structure at high concentration on the lipid membrane –
a process, which might play a role in myelin membrane
stacking [62].
The peptides PLP139-151 and PLPintra2 overlap,
PLPintra2 being an extended version of the widely used
encephalitogenic PLP139-151 peptide. Furthermore, the
region covered by PLPintra2 corresponds nearly exactly
to the segment missing in the alternatively spliced
DM20 isoform of PLP. DM20 is believed to be less adhe-
sive in membrane multilayers than PLP [63]. The factouring is shown in the legend, and the segment missing in DM20 is
Helical wheel of a predicted amphipathic helix in the PLPintra2 (and
lf of the PLPintra2 peptide, based on the PEP-FOLD model. d Behaviour
l spectra for a TFE titration series (shown here for the PLPintra1 peptide),
s. e Conventional CD spectra of the PLP peptides (left to right: PLPintra1,
PC/DMPG vesicles
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DM20 show clear, strong folding events in membrane-
like environments suggests that indeed, a membrane-
binding site is removed from DM20 during alternative
mRNA splicing. It is likely that this segment folds into
an amphipathic helix onto the membrane surface
(Fig. 6c); this propensity should be further strengthened
by hydrophobic post-translational modifications (palmi-
toylation) on the two Cys residues, as suggested by a
helical wheel representation (Fig. 6b).
The palmitoylation of the Cys residues has been ob-
served to induce greater T cell and antibody responses
in both EAE mice and MS patients compared to nonacy-
lated peptides [64, 65]. This further supports the rele-
vance of the hydrophobic surface of an amphipathic
helix to the immunogenicity of PLP139-151 and PLPin-
tra2 peptides. We believe that this segment is a strong
membrane anchor in PLP. Whether it binds to the same
or the apposing membrane surface in myelin, is cur-
rently unknown. Both scenarios would explain stronger
adhesive properties of PLP in comparison to the DM20
isoform.
During evolution, the 35-residue segment distinguish-
ing PLP from DM20 has been acquired in terrestrial ver-
tebrates [63, 66]. Simultaneously, the expression of
myelin protein zero (P0) in the CNS has been lost. This
points towards a scenario, where the evolution of terres-
trial vertebrates at the myelin molecular level has in-
volved the loss of P0-mediated adhesion (which still is
crucial in the PNS) and the acquirement of an additional
adhesive segment in the cytoplasmic domain of PLP/
DM20. PLP has a strong tendency to form dimers in
transfected COS cells, primary oligodendrocytes, and in
brain tissue, while DM20 exists mainly as a monomer.
Cys108, located in the common part of intracellular loop
of PLP/DM20, as well as in the PLPintra1 peptide, is in-
volved in the dimerization of PLP [67].
Both the PLP139-151 and PLPintra2 peptides include
a ‘stop transfer signal’ (residues HPDK150), which re-
stricts the ability of transmembrane helix 3 to shift in
the cases of mutations in the second extracellular loop
of PLP. These charged residues are omitted from DM20,
enabling the movement of the transmembrane domain
inside the membrane [68]. Thus, in some cases, the mid-
dle part of the PLPintra1 peptide (residues GLSAT115)
forms an extension of transmembrane helix 3 and can
be embedded into the membrane. Several PLP139-151
epitope-mimicking peptides, not studied here, are also
known e.g. from Acanthamoeba castellanii [69] and Hae-
mophilus influenza [70]. Whether they share properties
with PLP139-151 remains a subject for future research.
The second extracellular loop of PLP contains two di-
sulphide bonds, located between Cys183-Cys227 and
Cys200-Cys227, respectively. The membrane-proximaldisulphide bond (Cys183-Cys227) is fundamental to the
proper cell surface expression of PLP, and it is involved
in Pelizaeus–Merzbacher disease [71]. The PLPextra2
peptide contains only two Cys residues (Cys183 and
200) and cannot form these disulphide bonds. However,
all membrane-mimicking conditions induced an α-
helical folding of the PLPextra2 peptide (Fig. 6d, e and
Additional file 5: Table S2). Dhaunchak and Nave [71]
also reported that the cell surface expression of PLP can
be rescued if the cysteines in the second extracellular
loop are mutated, indicating that the disulphide bonds
are not crucial for the normal folding of the second
extracellular loop.
The deconvolution of spectral data suggested 30–40%
helical content in membrane vesicles for PLPextra2 and
PLPintra1, which is consistent with the de novo pre-
dicted situation with partially folded and disordered state
(Table 1). Although the change in spectrum indicated in-
creased α-helical nature for PLPintra2, the calculated
content of α helices was modest. This may be an under-
estimate due to putative aggregation, which is discussed
below.
Membrane-induced folding of the GBS epitope from
human peripheral nerve protein P2
P2 is one of the structurally best-characterized myelin
proteins, being highly expressed in PNS myelin [72, 73].
It is a proposed target of autoimmune reactions in GBS,
and P2 peptides can be used to induce EAN, the mouse
model of human GBS [74, 75]. P2 is able to stack lipid bi-
layers together in an ordered manner in vitro [41, 76, 77],
and the P2 knockout mouse has changes in myelin lipid
composition and motor nerve conduction velocity during
periods of active myelination [73].
The peptide studied here corresponds to the GBS epi-
tope characterized earlier [78], and in the crystal struc-
ture, it comprises the first α helix of the lid of the 10-
stranded β-barrel structure [44] (Fig. 7a). It is likely that
the helical lid is centrally involved in membrane interac-
tions during membrane stacking [79].
The P2gbs peptide showed helical folding at DPC and
SDS concentrations above the CMC, and strong helical
folding was present at 30% TFE (Fig. 7b–d). With lipid
vesicles, a helical spectrum was observed in SRCD ex-
periments, further indicating induction of α-helical fold-
ing of P2gbs in membrane-like conditions (Fig. 7e).
While these results are not unexpected in light of de
novo predictions (Table 1, Additional file 3: Figure S2)
and the fact that the sequence is helical in the crystal
structure and predicted to contact the membrane, they
provide striking similarity to the CNS antigen peptides
described above. Similar molecular mechanisms and
principles could, thus, be involved in demyelination-
related autoimmunity in the CNS and PNS.
Fig. 7 The GBS epitope in P2. a The GBS epitope corresponds to the first α helix in the P2 crystal structure [44]. The two helices form a lid,
proposed to interact with the myelin membrane and possibly open upon ligand entry and release [79]. b DPC titration. c SDS titration. d TFE
titration. e SRCD spectra with and without lipid vesicles
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agglutination
In SRCD, one generally can use shorter pathlengths,
and hence, much higher sample concentrations than
in conventional CD, which has the problem of light
intensity falling off at lower wavelengths. During
SRCD experiments, peptide-induced aggregation was
observed when lipid vesicles were added into solu-
tions of high (0.5 mg/ml) concentrations of peptides.
This was most severe for the EB-mimic, MOG35-55,
and PLPintra2 peptides (data not shown). The prob-
lem could be circumvented by using lower peptide
concentration (0.25 mg/ml) with a high (1:100) pepti-
de:lipid ratio in SRCD experiments; this observation
also triggered us to investigate the agglutination po-
tency of the studied peptides more closely.
The monitoring of lipid vesicle aggregation was done
by measuring absorption (turbidity) at 450 nm after mix-
ing vesicles with increasing concentrations of peptides
(Fig. 8a). Although the peptide-induced aggregation was
modest compared to protein P2-induced agglutination
(Fig. 8b), reproducible vesicle agglutination was detected
for the EB-mimic, hMOG35-55, mMOG35-55, and
PLPintra2 peptides, and occasionally also for IA-mimic
and PA-mimic (Fig. 8 and data not shown). The observa-
tion of turbidity could indicate a propensity of the
peptide to stack membrane bilayers together into multi-
layers (mimicking myelin); in the least, it is a sign of
altered surface properties of the lipid membrane, pro-
moting aggregation. Hence, we consider turbidity a func-
tional assay for myelin membrane-stacking proteins/
peptides. Having this property not only in myelin proteinpeptides, but also in some of the molecular mimics, fur-
ther indicates common properties for the studied en-
cephalitogenic peptides.
Discussion
Despite huge efforts in the past decades, MS has so far
evaded the deciphering of its pathogenesis. We do know
that in rodent EAE models, an active immunization with
myelin antigens, or a passive adoptive transfer of
myelin-specific autoreactive Th1/Th17 CD4 lympho-
cytes, phenocopies many features of MS [80–82]. There
exists also understanding that the genetic susceptibility
via the HLA-DR15 haplotype and certain environmental
factors, such as infection by herpes viruses, especially by
Epstein-Barr virus, are significant risk factors for MS
[83]. However, we do not know whether induction of
autoimmunity in MS takes place primarily in the periph-
ery (like in EAE) or in the CNS. In the early stages of
MS, the presence of infiltrated T lymphocytes predomi-
nates, while in later stages, CNS inflammation becomes
self-sustainable, and the number of B cells in lesions in-
creases [2]. However, we do not know the relative im-
portance of CD4 and CD8 T cells or the exact roles of B
cells and antibodies. Finally, although the structural
similarity between the MHC II-bound MBP-derived pep-
tides and their molecular mimics, like those from EBV
polymerase, can explain how the mimic-specific TCRs in
CD4 T cells can recognize self-antigens [84, 85], we lack
structures of MBP/mimic-bound MHC I complexes. The
latter are important, as cytotoxic CD8 T cells can
directly attack the oligodendrocytes, which present pep-
tides to them [86]. Neither do we know whether the
Fig. 8 Turbidimetric analysis of all studied peptides. a Turbidity of each peptide-vesicle mixture was determined after a 10-min incubation. b The
human myelin protein P2 acts as a positive control for the assay. Note how concentrations above 10 μM decrease turbidity; this is caused by
precipitation of the vesicle aggregates
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those in MOG, may be induced by mimicking antigens.
MBP is the best-characterized myelin protein, both at
the level of the full-length protein and as peptide seg-
ments. Much of the early research was carried out using
MBP purified from tissue [20–25, 27], and more re-
cently, recombinant MBP has also been intensively stud-
ied [29, 30, 48, 49]. According to the current view, MBP
is intrinsically disordered in solution, but folds into short
helical segments upon membrane binding [87]. The
structure of MBP on membranes can be further affected
by the lipid composition. Here, we did not assess the ef-
fects of different lipid compositions on peptide folding,
but earlier research has shown that the helical structure
of the autoimmune epitope of MBP does slightly change
in different lipid membrane compositions [45, 88]. This
is of interest because demyelination is linked to changes
in lipid composition, and these changes may in turn alter
the conformation, localization, and properties of MBP
[89]. Furthermore, the epitope conformation may be af-
fected by its presence in either a peptide or a full-length
MBP protein [46, 47]. For obtaining detailed localconformational information, we chose here to focus on
short peptide segments. Even for the longest peptides,
we believe that the membrane-binding segments will be
short helices, as predicted de novo (Additional file 3:
Figure S2).
How do our observations of the common membrane-
induced folding of MBP mimics, and most other pep-
tides studied here, fit into this big picture? It is possible
that the propensity to adopt α-helical structure in the
experiment merely illustrates similar biophysical proper-
ties. However, it is also possible that these peptides do
adopt a helical structure in vivo, with relevance to the
generation of autoimmunity per se. Two speculative hy-
potheses can be presented.
Firstly, the relatively low affinity and non-standard
geometry in the binding of TCRs to MHC II-peptide
complexes can explain the escape of self-reactive T cells
from negative selection [90]. In the known MHC II-
MBP/mimic structures, the peptide binds MHC in an
extended conformation [84, 85]. Whether the peptide
propensity to fold affects rescue from negative selection
is not known. It can be speculated that during the
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loadable non-folded self-peptides is low, but may be-
come significant after inflammatory insult. Interestingly,
the presence of autoantigenic MBP peptides in the
spectrum of proteasomal products increases after MBP
immunization [86]. Secondly, it is possible that mimic-
specific, such as Epstein-Barr virus-infected and CNS-
infiltrated, memory B cells [91] may have affinity against
myelin neoepitopes that are exposed in degenerated/
insulted myelin.
Neither scenario above suggests that membrane-
induced folding universally leads to auto-immunogenicity,
but it could be relevant in rare cases where both 1) the
environment-induced conformational changes of myelin
proteins can lead to changes in processing and/or peptide
loading to affect negative selection of T cells or creation of
neoepitopes for B cells and 2) the mimicking agent is
present at the critical time. It is obvious that many hydro-
phobic self-sequences are strongly immunogenic [92, 93],
but the corresponding T cells go to apoptosis in the thy-
mus. An animal model with genetic or external exposure
of myelin proteins/peptides, which do not significantly
change the structure of the host protein, but alter
membrane-induced conformational changes, might be
useful to test these hypotheses.
Conclusions
The understanding of myelin autoimmunity at the mo-
lecular level is poor, also taking into account the fact
that myelin protein epitopes in general are buried
within the myelin sheath, a tightly packed multilayered
membrane. On the other hand, these epitopes are hid-
den from the immune system in a healthy myelin en-
vironment, and might only be exposed in case of prior
insult to the myelin membrane. All our experiments
point towards highly similar properties for all the stud-
ied peptides. In this respect, it is of interest to note
the possible potential of myelin protein-derived pep-
tides in MS therapy; these include both cyclic and mu-
tated variants of myelin antigen peptides, especially
MBP85-99 [59, 94–98]; the design of such peptides
could also take into account our observations on simi-
lar overall structural and membrane interaction prop-
erties of peptides with limited sequence similarity per se.
While the link between membrane binding, membrane-
induced folding, and autoimmune response is unclear,
molecular mimicry possibly taking place in autoimmune
demyelination may be based on 3D similarity of host
and pathogen epitopes. In the case of MBP85-99
mimics, for example, while the peptides fold into
amphipathic helices on lipid membranes, the extended
conformation bound to the MHC shows the con-
served residues being presented outwards, being im-
portant for immune response.Our results give new insights into myelin protein-
membrane interactions within short segments of the
protein; the situation in the case of full-length proteins
is of course more complex. For protein-peptide interac-
tions, both electrostatic interactions and conformational
flexibility are important factors in recognition and bind-
ing [99]. In the case of flexible proteins, such as MBP, a
multitude of conformations are present [29, 87], and
antibody binding might reflect a fortuitous capture of
specific conformations that become more rigid. The
conformations of MBP peptides on the membrane sur-
face and when bound to MHC may reflect such a
phenomenon. Similar properties between different pep-
tide epitopes may provide means to multifaceted, but
shared, recognition mechanisms, which in turn may re-
late to disease etiology. It is clear that more research in
in vivo systems will be required to gain further answers to
these questions in the case of autoimmune demyelination.Additional files
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